Vortioxetine not checked

Takeda · H. Lundbeck A/S · Lu AA21004

FollowEvery change as it happens, and a Monday email
Stage
in the US and EU
Next date
Phase 3 trial completes
Trials
4 active
14 in total · 3 in the EU

What this is

How it works
How it works isn't classified yet
Tested for
Major Depressive Disorder
Main trialPhase 3
“The main aim of the study is to check how well vortioxetine 10 mg/day or 20 mg/day works and to check for side effects compared to a placebo on depression symptoms in Japanese teenagers aged 12 to 17 years with a diagnosis of Major Depressive Disorder (MDD). The overall time each participant will be in the study is about 20 weeks. This includes up to 15 days (about 2 weeks) to check who can take part, a 14-week period where everyone receives vortioxetine or a placebo, and after that, a 4-week period to check for any side effects after treatment. During the study, participants will visit…”In the company’s words, NCT07204314 on ClinicalTrials.gov
Other names
Lu AA21004 · Brintellix · Trintellix

Other drugs for Major Depressive Disorder

All 36 drugs for Major Depressive Disorder

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials14

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Sep 2029 A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Phase 4Completed 1 Mar 2019 Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
Phase 4Completed 9 Mar 2021 Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
Phase 4Completed 6 Jan 2022 Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
Phase 4Completed 11 Feb 2022 Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
Phase 4Completed 6 Jul 2022 Vortioxetine in Patients With Depression and Early Dementia
Phase 3Completed 16 Mar 2018 A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
Phase 3Completed 16 Apr 2020 Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
Phase 3Completed 21 Jan 2022 Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
Phase 3Terminated 25 Mar 2022 Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Phase 3Terminated 31 Mar 2022 Vortioxetine to Prevent Return of Symptoms in Children With Depression
Phase 4Authorised not given "SAFE DISCONTINUATION OF ANTIDEPRESSANTS IN INDIVIDUALS WITH CLINICALLY REMITTED DEPRESSIVE DISORDERS"
Phase 2/3Authorised not given Cognitive effects of adjuntive Vortioxetine in early Schizophrenia
Phase 4Authorised not given A multicenter randomized, controlled, single-blind, adaptive phase IV clinical trial to evaluate the efficiency and effectiveness of a pre-emptive pharmacogenetic strategy for antidepressant selection in patients with depressive disorder: The PREDICT adaptive clinical trial.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Vortioxetine

Following is part of Solo: you see every change to Vortioxetine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in